Find Funding Opportunities

The National Institutes of Health (NIH) announces the continuation of the U.S. entity of the U.S.-Japan Brain Research Cooperative Program (BRCP). This administrative supplement program will provide funds to currently active research grants that are currently supported by one of the participating NIH Institutes and Centers. This Notice is soliciting administrative supplements for the following mechanisms ONLY: DP1, DP2, DP1, DP2, DP5, R01, R03, R21, R33 , R34, R37, R61, U01, UH2, and UH3.The purpose of the BRCP is to promote scientist exchange, training, and collaborations in basic, translational and clinical research between neuroscientists from the U.S. and Japan.The U.S. entity of the BRCP supports the following activities:1) Visit of U.S. scientists to conduct collaborative research and/or to acquire advanced research skills in Japanese institutions,2) Joint workshops to exchange scientific information and to foster collaborations.

Reissue of PAR-20-122. The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize promising hit compounds through medicinal chemistry to the Development stage, to advance a single development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Alternatively, projects can enter at the Development stage and progress in a shorter period to IND enabling toxicology studies and phase I clinical testing. BPN awardee Institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN contractors (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program.

Reissue of PAR-20-111. The Blueprint Neurotherapeutics Network (BPN) encourages applications from small businesses seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize promising hit compounds through medicinal chemistry to the Development stage, to advance a single development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Alternatively, projects can enter at the Development stage and progress in a shorter period to IND enabling toxicology studies and phase I clinical testing. Projects that enter at the Discovery stage and meet their milestones may continue on through Development. BPN awardee institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN contractors (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program.

This Notice is to clarify the placement and inclusion for the Institutional Letter for RFA-MH-23-330 K99/R00 BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent Clinical Trial and RFA-MH-23-331 K99/R00 BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent Clinical Trial Not Allowed).

The purpose of the Clinical Trial Methods in Clinical Neurological Disorders Course" Funding Opportunity Announcement (FOA) is to increase the reliability and effectiveness of clinical trials and to enhance the training of investigators new to clinical trials.

The purpose of this initiative is to solicit applications for Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Centers. These Centers promote collaborative basic, translational, and clinical research, and provide important resources that can be used by the national muscular dystrophy research community. The Centers also provide outstanding environments for the training of new scientists electing to pursue careers conducting research in high priority areas of muscular dystrophy. Furthermore, Center investigators participate in community outreach efforts to increase awareness and convey the importance and implications of their research activities to the patient and advocacy communities.

The National Institute of Mental Health is issuing this Notice to replace PA-20-151, Eradication of HIV-1 from Central Nervous system Reservoirs (R01 Clinical Trial Not Allowed)

The National Institute of Mental Health is issuing this Notice to highlight interest in Neuropathogenesis of CNS Complications in People with HIV

The National Institute of Mental Health is issuing this Notice to highlight interest in Clinical Studies of CNS Complications in People with HIV

The National Institute of Neurological Disorders and Stroke (NINDS) intends to promote a new initiative by publishing a Notice of Funding Opportunity (NOFO) to solicit applications for research on Community-Engaged Health Equity Research in Neuroscience.This NOFO will solicit applicationsfor planning grants to assess feasibility and/or determine best practices to conduct community-engaged health equity research in neurological disorders with populations that experience health disparities (HDPs), that, if successful, would support, enable and/or lay the groundwork for a future clinical study or trial.In addition to posing a research question related to addressing health disparities in neurological disorders, applicants must also be filling a gap in 1) Community engagement with HDPs; and/or 2) Multidisciplinary research team expertise in neurological disorders, health disparities research and/or community engagement.Expected outcomes would advance understanding of drivers of health disparities and barriers to neurological health equity and establish collaborative research teams, including community partners, with appropriate expertise in community engagement with HDPs, health disparities research and neurological disorders.